partnering made easy - iqpc corporatethe ritz-carlton laguna niguel, ca october 5-7, 2016 partnering...

The Ritz-Carlton Laguna Niguel, CA October 5-7, 2016

Partnering Made EasyThe deal-making event for life science groundbreakers

Lead Sponsors:

The BioNetwork meeting was one of the best I have attended – I really liked the collegiate atmosphere and ability to have discussions without overwhelming crowds. The intimate setting works well and fosters new contacts/relationships.

Jeannie Joughin, Vice President, Corporate Development, Enable Injections

Between the content, the partnering meetings and social activities, I think it was a very rewarding experience that I would love to repeat.

Michal Preminger, Executive Director, Harvard University Office of Technology Development, Harvard Medical School Office

A solid meeting once again. I enjoyed the format , quality of speakers, and opportunity for 1:1 meetings. Obviously the location is very special and a real draw!!!

John Kaiser, VP Commerical & Business Development, Cerecor

The BioNetwork event is the best partnering event I attend because of the ability to network with so many industry colleagues.

Paul Resnick, Vice President and Chief Business Officer, MabVax Therapeutics, Inc.

Pharma/Big Biotechs - is your company speaking at BioNetwork? Call 1-888-482-6012 and get $600 off your ticket.

Partnering Made EasyBioNetwork West is the essential platform for business development executives across the pharmaceutical and biotechnology space to come together. You will develop relationships with true decision makers that lead to strategic partnerships, all done in a beautiful intimate setting. We make it easy for you to make lasting connections… and enjoy yourself while doing so!

Whether you’re looking for face time with big pharma for a potential partnership, or to meet with VCs to advance your programs, BioNetwork West has it covered. Here are just some of the companies confirmed to attend:

Top 10 Pharmaceutical Companies Confirmed

Who’s Looking For Partners

Novartis

Pfizer

Sanofi

Roche

Merck

Johnson & Johnson

GSK

Johnson & Johnson Innovation - JJDC, Inc.

MPM Capital

New Leaf Venture Partners

Orbimed Advisors LLC

Pfizer Venture Investments

Venture Capitalists Confirmed

AstraZeneca

Gilead Sciences

Teva Pharmaceutical Industries

Lead Sponsors:

Meet Your Speaking and Partnering Faculty John Adamou Head, Business Development and Licensing, Strategic Transactions Boehringer Ingelheim Pharmaceuticals, Inc.

Jeremy Ahouse Executive Director, Alliance Management Celgene *New*

Barbara Araneo Innovation Sourcing Director Novo Nordisk *New*

Robert Bagdorf Vice President of Worldwide Business Development Pfizer Inc.

Steven Bartz Director, Worldwide Licensing Merck

Simon Bateman Executive Director, Business Development & Licensing, Alliance Management Novartis Pharmaceuticals Corporation *New*

Michael Bayewitch Director, S&E, Biologics Teva

Lisa Beck Head of Transactions, Global Business Development Alexion Pharmaceuticals *New*

Neil Berkley Senior Director, Business Development GSK

Robert Breuil Chief Financial Officer Corium International *New*

Pablo J. Cagnoni Managing Director MPM Capital *New*

Hemmie Chang Chair, Licensing & Strategic Alliances Practice Group Foley Hoag

Leon Chen Venture Partner Orbimed Advisors LLC *New*

Ashlee Dunston Director of Healthcare Research Guidepoint

Luke Düster Managing Director CRG

Mike Dybbs Partner New Leaf Venture Partners *New*

Van W. Ellis Partner Morrison & Foerster

M. Johnston Erwin Vice President, Corporate Business Development Eli Lilly and Company *New*

Adi Frish Senior Vice President, Business Development and Licensing Redhill Biopharm LTD

Patrick Gallagher Vice President, Business Development Noven Pharmaceuticals

Peter Ginsberg Senior Director, Business Development United Therapeutics *New*

Jonathan Gertler Managing Partner & CEO Back Bay Life Science Advisors

Scott E. Goedeke President Viscadia

Kathryn Gregory Executive Director, Business Development Purdue Pharma *New*

Todd Haim Program Director, NIH National Cancer Institute Small Business Innovation Research (SBIR) Development Center

Christian Hordo Head of Business Development Juno Therapeutics *New*

Patrick Johnson Vice President of Business Development Allergan *New*

Elaine V. Jones Executive Director, Venture Capital Pfizer Inc. *New*

Neena Kadaba Director, Industry Alliances QB3

Lawrence Klein Vice President, Strategy CRISPR Therapeutics *New*

Kevin Lynch Vice President, Scientific Assessment AbbVie *New*


Stuart Mackey Global Head of Business Development Daiichi Sankyo *New*

Adam Marcus Principal DRI Capital

Timothy Morris Chief Financial Officer, Head of Business Development AcelRx *New*

Kia Motesharei Head, Global Licensing & Business Development, Immunology Merck KGaA, Darmstadt, Germany

Catherine Pickering Head of Oncology & Immuno-Oncology Licensing Merck KGaA, Darmstadt, Germany *New*

Christoph Pittius Vice President, Head of Transactions AstraZeneca

Prakash Raman Vice President, Global Head of Oncology BD&L Novartis *New*

Speaking & Partnering Faculty Continued

Paul Resnick Vice President and Chief Business Officer MabVax Therapeutics, Inc. *New*

Melinda Richter Head of JLABS Johnson & Johnson Innovation *New*

Scott Shaunessy Chief Executive Officer ideaPoint Inc.

Shehnaaz Suliman Vice President, Roche Partnering Roche *New*

Kumar Srinivasan Vice President, Scientific Partnering and Alliances & Site Head Waltham R&D AstraZeneca *New*

Alex Szidon Executive Director, Business Development & Licensing, Head, West Coast Innovation Hub Merck *New*

Andre Turenne Global Head of Business Development & Licensing Sanofi *New*

Johan Verbeeck Head, External Partnering Strategy J&J Innovation Janssen, Pharmaceutical Companies of Johnson and Johnson *New*

Monica Viziano Senior Director, Alliance Management, Corporate Development Gilead Sciences *New*

Joe Whalen Senior Vice President, Business Development & Alliance Management Horizon Pharma *New*

Asish K. Xavier Vice President, Venture Investments Johnson & Johnson Innovation – JJDC, Inc. *New*

“ “Always one of my favorite conferences-the size, the people, the opportunities to interact with colleagues, and of course, the venue”Patrick Gallagher, Vice President of Business Development, Noven Pharmaceuticals, Inc.

1-888-482-6012 or 1-646-200-7530 · [email protected] · www.bionetworkwest.com Register Now!

1:1 Partnering MeetingsTake advantage of these scheduled 30-minute meetings throughout the event – you’ll meet other deal makers in a comfortable, private room to have the conversation you need to drive your business forward. The 1:1 Partnering Meetings will run concurrent to the conference sessions.

How It Works:

1Get registered! Four weeks before BioNetwork West you’ll receive instructions on how to register on the partnering site.

2Create a hotlist! You’ll have access to the list of participating companies and executives, as well as their offerings and partnering objectives – you’ll be able to select who you want to meet based on your needs.

3Start messaging! The easy-to-use system allows you to request and accept meetings, and message attendees.

4 Get accepted! After both parties accept the meeting request, the system will slot you into a private meeting room that fits your schedules. Invite your colleagues to join, move appointments, and communicate with attendees with ease.

5All day, every day! The partnering site is live throughout the event and you can access it on your mobile device.

Please contact Caitlin Vance with any questions regarding the one-to-one partnering site: [email protected].

“The partnering program allowed me to

schedule one-on-one meetings with representatives of fourteen of

the largest pharmaceutical companies throughout the world.

I do not think any other conference is able

to provide such a comprehensive series of sessions with similar types of participants.”

Benjamin A. Belinka, Jr., CEO/President, Actinobac Biomed

Hosted by:

http://bit.ly/1sYQH6v

Lead Sponsors:

Your Networking Experience

Start the event getting to know peers with similar interests as you. Choose your focus area, then sit with 10 – 15 others looking for and debating the best way to carry out similar opportunities.

Thursday, Oct 6 at 5:05pmPlace your bets, win some prizes and strengthen business relationships in a relaxed, yet somewhat competitive environment. Casino Night is a BioNetwork favorite, don’t miss out!

Wednesday, Oct 5 at 5:40pm

Meet and network with new

contacts as you take in views of the beautiful

sunset over the Pacific Ocean.

Thursday, Oct 6 at 6:30amGet your heart pumping and blood flowing before a full day of meetings. Both your body and your virtual rolodex will be healthy

at BioNetwork. All paces welcome.

Ice Breaker Roundtables

Monte Carlo Casino Night

Bocce Ball And Beer

Sunset Cocktail Reception

Sunrise Jog

Tuesday, Oct 4 at 5:30pmCheck into the hotel then join other attendees on the Sunset Terrace for a casual game of bocce ball while you sip an ice cold beverage.

Get Noticed During The Biotech SpotlightsElevate your company’s exposure at BioNetwork West with a 15-minute presentation as a Biotech Spotlight. This is your platform to get in front of decision makers to highlight your technology and the partnerships and opportunities you’re seeking.

• Capture the attention of the industry’s most senior business development executives to get on their radar

• Present your novel technology and innovations to an international audience of decision makers to advance your next deal

• Be featured in our program guide and on the website to gain exposure for your presenter and company

• Opt for one of the two remaining Premium Biotech Spotlights and address the full conference audience before the 1:1 meetings open to gain broader reach and advance your program.

There are a limited number of spotlight opportunities available, contact Mimi Fox for additional information at 416-597-4808 or [email protected]

“BioNetwork provides an excellent

forum for small biotechnology companies to interact 1 on 1

with key decision makers at both leading pharmaceutical and life science

companies. The atmosphere is more relaxed than many large industry

conferences, enabling conversations and presentations that lead to decisions and follow

up vs. the normal meet and greet churn. Was definitely worth my time.”

Evan Lippman, Chief Financial and Business Officer, Aileron Therapeutics, Inc.


On-The-Go Partnering With the AppWe know travel schedules are tight and you shouldn’t have to wait to be at your computer to take control of your partnering experience. Through the all new mobile app you can:

• Schedule and accept meetings

• Access the attendee list and message participants

• View your partnering schedule and the conference agenda

• Block out your schedule with must-attend biotech spotlights and panels

• And more!

Hosted by:


The Ultimate LocationResting atop a 150- foot bluff above the coast line, the Ritz Carlton Laguna Niguel is all about luxury. Respond to email (if you must) while watching the sun set over the Pacific, or in between services at the spa. Dine at, or order room service from some of the top restaurants in Southern California. You’ll never need to leave the hotel – in fact, you’ll never want to.

An Annual Sell-Out VenueBioNetwork West has procured a special conference rate of $325 per night (plus tax). To book your reservations, call The Ritz-Carlton, Laguna Niguel at 1-877-266-6065 and identify yourself as a BioNetwork attendee. Rooms are limited and are on a first come, first served basis, so make your reservations as soon as possible. The discounted rate expires September 9th, 2016. After September 9th, rooms may still be available, so inquire with the hotel if you have missed the cut off date. We advise to book early, rooms do sell out every year.

Relax, Refresh and Revitalize Yourself and Your Pipeline at The Ritz


Pre-Event Networking ActivityT U E S DAY, O C TO B E R 4 , 2 0 1 6 AT 5 : 3 0 P M

Bocce Ball And Beer On The Sunset Terrace

Check into your hotel room and join us for an ice cold beverage and a friendly game of bocce ball on the Sunset Terrace. Unwind during this informal activity, meet fellow attendees and potential partners as you gear up for three days of more formal partnering activities.


Day One: The Latest Trends in Biopharma Partnering W E D N E S DAY, O C TO B E R 5 , 2 0 1 6

7:40 Registration And Networking Breakfast

8:40 Welcoming Remarks Marissa Alvord

Executive Director BioNetwork

8:45 Chairperson’s Opening Address Jonathan Gertler

Managing Partner & CEO Back Bay Life Science Advisors

9:00 Therapeutic Focus Area Ice Breaker Roundtables

Kick-start your partnering experience meeting those who prioritize the same therapeutic areas as you! Find out the latest priorities in the biggest therapeutic areas and current opportunities available. Discuss goals, common industry challenges and firm up your personal partnering objectives for the next three days.

#1 Oncology Todd Haim

Program Director NIH, National Cancer Institute, Small Business Innovation Research (SBIR) Development Center

to your next deal, or demonstrate your technology to the full conference audience. See page 8 for additional information.

BIOTECH SPOTLIGHT | Redhill Biopharm LTD.

Adi Frish Senior Vice President, Business Development and Licensing Redhill Biopharm LTD

9:45 Biotech Spotlight

10:00 Opening Of 1:1 Partnering -1:10 Meetings These will run concurrent to the

conference sessions throughout the entire day!

See page 6 for how to get the most out of these meetings.

10:00 PANEL DISCUSSION | Going beyond PD-1 and PD-L1, Future Opportunities in Immunotherapies · What are the latest opportunities

for immunology in areas such as cell therapy?

· Just how many immunotherapies can you put checkpoints on top of?

· What are the newest opportunities for combination therapies in immunology?

#2 Immunology Kia Motesharei

Head, Global Licensing & Business Development, Immunology Merck KGaA, Darmstadt, Germany

#3 Immuno-oncology Paul Resnick

Vice President and Chief Business Officer MabVax Therapeutics, Inc.

#4 Rare and Orphan Diseases Joe Whalen

Senior Vice President, Business Development & Alliance Management Horizon Pharma

#5 Pain Kathryn Gregory

Executive Director, Business Development Purdue Pharma

#6 Gene Therapy #7 Neurodegenerative Diseases #8 Cardiovascular Disease

9:30 Premium Biotech Spotlight Series

Before the 1:1 meetings commence, two innovative biotech companies will provide a 15-minute overview of their latest technologies. Find out the latest innovations that could be critical

Moderator: Stephan Gauldie Senior Vice President Back Bay Life Science Advisors

Christian Hordo Head of Business Development Juno Therapeutics

Catherine Pickering Head of Oncology & Immuno-Oncology Licensing Merck KGaA, Darmstadt, Germany

Prakash Raman Vice President, Global Head of Oncology BD&L Novartis

Paul Resnick Vice President and Chief Business Officer MabVax Therapeutics, Inc.

10:40 Networking And Refreshment Break

11:10 PANEL DISCUSSION | Current and Future Opportunities in Gene and Cell Therapies · Which areas are ripe for cell and

gene therapy, which areas are inapplicable?

· How are new deals being developed for these new technologies?

· With a curative approach, what is the future for cell and gene therapy?

For detailed session descriptions, please visit www.BioNetworkWest.com.


Lead Sponsors:

Moderator: Hemmie Chang Chair, Licensing & Strategic Alliances Practice Group Foley Hoag

Jeremy Ahouse Executive Director, Alliance Management Celgene

Simon Bateman Executive Director, Business Development & Licensing, Alliance Management Novartis Pharmaceuticals Corporation

Lawrence Klein Vice President, Strategy CRISPR Therapeutics

Kumar Srinivasan Vice President, Scientific Partnering and Alliances & Site Head Waltham R&D AstraZeneca

11:50 NCI Introduction Todd Haim

Program Director NIH, National Cancer Institute, Small Business Innovation Research (SBIR) Development Center

11:55 Biotech Spotlight Oncology Showcase

Hear from innovative oncology focused biotech companies who will

provide a 15-minute overview of their latest technologies. Find out the latest innovations that could be critical to your next deal, or demonstrate your technology to an audience looking for their next deal. See page 8 for additional information.

1:10 Networking Luncheon

2:10- 1:1 Partnering Meetings 5:40 Continued These will run concurrent to the



2:10 PANEL DISCUSSION | The Equities Market of 2016, What is Possible? · Where can you find money in public

markets currently? · What creative financing is being

done? · How are companies finding money to

launch? Moderator:

Luke Düster Managing Director CRG

Robert Breuil Chief Financial Officer Corium International

W E D N E S DAY, O C TO B E R 5 T H , 2 0 1 6

Timothy Morris Chief Financial Officer, Head of Business Development AcelRx

Joe Whalen Senior Vice President, Business Development & Alliance Management Horizon Pharma

2:50 PANEL DISCUSSION | Successfully Capturing the Attention of Big and Mid-Sized Pharma · What are the top 5 do’s and don’ts for

the pitch deck? · What is the process for getting on their

radar? · How do you effectively progress

discussions? Moderator:

Greg Benning Managing Director, Head of Financial Advisory Back Bay Life Science Advisors

Neil Berkley Senior Director, Business Development GSK

Kevin Lynch Vice President, Scientific Assessment AbbVie

Kia Motesharei Head, Global Licensing & Business Development, Immunology Merck KGaA, Darmstadt, Germany


Shehnaaz Suliman Vice President, Roche Partnering Roche

Monica Viziano Senior Director, Alliance Management, Corporate Development Gilead Sciences


4:00 Biotech Spotlight Showcase Hear from innovative biotech

companies who will provide a 15-minute overview of their latest technologies. Find out the latest innovations that could be critical to your next deal, or demonstrate your technology to an audience looking for their next deal. See page 8 for additional information.

5:00 PANEL DISCUSSION | Establishing Innovation Hubs to Build the Pipeline · How do different innovation hubs

compete or differentiate themselves? · What is the role of geography and

how can geography be used for advantage?

· What is next on the horizon for innovation centers?

Moderator: Christopher Leo Senior Vice President Back Bay Life Science Advisors

Barbara Araneo Innovation Sourcing Director Novo Nordisk

M. Johnston Erwin Vice President, Corporate Business Development Eli Lilly and Company

Neena Kadaba Director, Industry Alliances QB3

Melinda Richter Head of JLABS Johnson & Johnson Innovation

Alex Szidon Executive Director, Business Development & Licensing, Head, West Coast Innovation Hub Merck

5:40 Sunset Cocktail Reception

W E D N E S DAY, O C TO B E R 5 T H , 2 0 1 6


Day Two: Innovative Dealmaking

T H U R S DAY, O C TO B E R 6 , 2 0 1 6

6:30 Sunrise Jog

7:45 Registration And Networking Breakfast

8:45 Welcoming Remarks Marissa Alvord

Executive Director BioNetwork

8:50 Chairperson’s Opening Address

9:00 Premium Biotech Spotlight Series

Before the 1:1 meetings commence, two innovative biotech companies will provide a 15-minute overview of their latest technologies. Find out the latest innovations that could be critical to your next deal, or demonstrate your technology to the full conference audience. See page 8 for additional information.

9:30 Opening Of 1:1 Partnering -1:05 Meetings These will run concurrent to the



10:40 PANEL DISCUSSION | From Sourcing to Alliance Management, The Ins and Outs of Hybrid Deals

The industry continues to evolve toward evermore complex transactions for the development and commercialization of products. With the increasing complexity of deal structure and collaboration objectives, effective alliance management requires new tools and approaches.

· Overview of emerging practices for deals that rely heavily on partnerships

· Establishing governance and strategies to optimize the prospects for success

· Working toward alignment internally and externally on global deals

Moderator: Van W. Ellis Partner Morrison & Foerster

Panelists to be confirmed



12:35 Networking Luncheon

9:30 PANEL DISCUSSION | The Evolution of Risk Sharing Models in Today’s Market · Overview of the latest variations on

risk sharing · How are up front payments being

minimized? · What are the different investment

vehicles being used? Moderator:

Scott E. Goedeke President Viscadia

Peter Ginsberg Senior Director, Business Development United Therapeutics

Patrick Johnson Vice President of Business Development Allergan

Stuart Mackey Global Head of Business Development Daiichi Sankyo

Christoph Pittius Vice President, Head of Transactions AstraZeneca


1:35- 1:1 Partnering Meetings 5:40 Continued These will run concurrent to the



1:35 PANEL DISCUSSION | A Thorough and Swift Approach to Due Diligence · What are the key challenges in

conducting diligence? · What do you perceive to be the key

challenges? · What approaches are most effective

in getting validated insights faster? Moderator:

Ashlee Dunston Director of Healthcare Research Guidepoint

John Adamou Head, Business Development and Licensing, Strategic Transactions Boehringer Ingelheim Pharmaceuticals, Inc.

Robert Bagdorf Vice President of Worldwide Business Development Pfizer Inc.


Lead Sponsors:

T H U R S DAY, O C TO B E R 6 T H , 2 0 1 6

Patrick Gallagher Vice President, Business Development Noven Pharmaceuticals

Kathryn Gregory Executive Director, Business Development Purdue Pharma

Adam Marcus Principal DRI Capital

2:15 PANEL DISCUSSION | From Disruptive to Traditional, The Latest Trends in VC Funding · What are the latest developments

in the emerging model of companies started by VCs?

· What is the current appetite for risk across the biopharma venture community?

· How do strategies differ from large VC to new venture funds?

Pablo J. Cagnoni Managing Director MPM Capital

Leon Chen Venture Partner Orbimed Advisors LLC

Mike Dybbs Partner New Leaf Venture Partners

Elaine V. Jones Executive Director, Venture Capital Pfizer Inc.

Asish K. Xavier Vice President, Venture Investments Johnson & Johnson Innovation – JJDC, Inc.




4:25 PANEL DISCUSSION | Key Strategies for Success in Early Stage Partnering · What data are buyers looking for? · How can you best differentiate your

product in a crowded space? · With pharma and VCs taking a

greater interest in early stage opportunities, what can biotech and academic institutions do to be most competitive?

Moderator: Scott Shaunessy Chief Executive Officer ideaPoint Inc.

Steven Bartz Director, Worldwide Licensing Merck

Michael Bayewitch Director, S&E, Biologics Teva

Lisa Beck Head of Transactions, Global Business Development Alexion Pharmaceuticals

Andre Turenne Global Head of Business Development & Licensing Sanofi

Johan Verbeeck Head, External Partnering Strategy J&J Innovation Janssen, Pharmaceutical Companies of Johnson and Johnson

5:05 Monte Carlo Casino Night


Day Three: Connecting Dealmakers

F R I DAY, O C TO B E R 7 , 2 0 1 6

8:30 Closing Mimosa Brunch Begins

9:00- Opening Of 1:1 Partnering 12:00 Meetings These will run concurrent to the conference sessions throughout

the entire day!


9:00 Partnering Opportunity Roundtables Round out your partnering experience discussing forward looking topics and

trends in partnering. After two action-packed days, have a mimosa, connect with those you haven’t had an opportunity to meet with yet and discuss lessons learned in recent deals and devise strategies to influence future deals.

#1 The Impact of Recent Stock Price Movements on Partnering Discussions

#2 Best Practice Methods to Manage Different Deal Structures #3 Lessons Learned in Managing Poorly Run Processes #4 Short- and Long-term Alliance Management Strategies #5 Biotech CEO Meet-up: Lessons Learned At Different Stages in the

Lifecycle

12:00 Conclusion of BioNetwork West 2016


BioNetwork West 2016 Attendees

Company Job Title Therapeutic Area

A. Menarini I. F. R. Corporate Licensing Director Allergy, Andrology, Anit-invective, Cardiovascular, Dermatology, Gastrointestinal, Gynoclolgical, Pain, Respirology, Reumatology

A. Menarini I.F.R. Senior Licensing Manager Allergy, Andrology, Anit-invective, Cardiovascular, Dermatology, Gastrointestinal, Gynoclolgical, Pain, Respirology, Reumatology

AADI & AADIGen CEO oncology, cardiovascular and metabolic disease

Abbvie Scientific Assessment Vice President immunology, kidney disease, oncology, neuro science, liver disease and women's health

ACEA Biosiences Inc. Vice President of Business Development - Therapeutics Immunotherapy, cell therapy

AcelRx Pharmaceuticals Inc Chief Financial Officer and Head of Business Development acute and breakthrough pain

AcelRx Pharmaceuticals Inc Alliance Management and Corporate Development Director acute and breakthrough pain

Adare Pharmaceutical Senior Business Development Director Cardiovascular, pain management, GI and CNS

Aeterna Zentaris President & CEO Oncology, Endocrinology

Aeterna Zentaris VP Business Development Oncology, Endocrinology

Affimed Therapeutics Buisiness Development Director Oncology, Immuno Oncology

Albion Laboratories, Inc Senior Licensing Director and Special Counsel nutritional supplements

Albumedix Director of Business Development drug delivery

Alexion Pharmaceuticals, Inc Global Head of Business Development and Transactions devastating and rare diseases

Allergan, Inc. Business Development Vice President Dermatology and Aesthetics, CNS, Eye Care, Women’s Health and Urology, GI and Cystic Fibrosis , cardiovascular and infectious disease

Amgen Executive Director Business Development

bone health, cardiovascular, hematology, oncology, inflammation, metabolic disorders, nephrology, neuroscience

Amunix President & CEO Oncology

Arbor Pharmaceuticals Business Development Manager cardiovascular, primary care, CNS and pediatrics

Assembly Biosciences Vp - Corp Dev & Strategy infectious diseases

Assembly Biosciences Manager, Corp Dev & Strategy infectious diseases

Assembly Biosciences Director of Project Management infectious diseases

Astellas Innovation Management Associate Director cardiology, dermatology, immunology, infectious disease, oncology and

urology

AstraZeneca VP, Head of Transactions, Business Development

cardiovascular & metabolic, gastrointestinal, infection, neuroscience, oncology, respiratory, inflammation and autoimmunity

AstraZeneca Head of Scientific Partnering and Alliances

cardiovascular & metabolic, gastrointestinal, infection, neuroscience, oncology, respiratory, inflammation and autoimmunity

Autotelic CEO medical device company in cardiovascular and oncology

Back Bay Life Science Advisors Managing Partner, CEO strategy consulting and financial advisory services for life science

companies

Back Bay Life Science Advisors Sr. Vice President strategy consulting and financial advisory services for life science

companies


Back Bay Life Science Advisors Managing Director strategy consulting and financial advisory services for life science

companies

Back Bay Life Science Advisors Senior Vice President strategy consulting and financial advisory services for life science

companies

BioPharm Insight North American Sales Director life science market intelligence and analytics solution

BioPharm Insight Business Development Director life science market intelligence and analytics solution

BioPharm Insight Product Manager life science market intelligence and analytics solution

Boehringer Ingelheim Head, Bd&l - Strategic Transactions immunology & respiratory diseases, cardiometabolic diseases, central nervous system diseases, and oncology.

Bristol Myers Squibb Transaction Lead of Biologics Discovery California

cardiovascular, immuno-oncology, oncology, immunoscience, virology, fibrotic disease, genetically defined diseases, metabolics

Canton Laboratories - Laser Pharmaceuticals President Pain and Generics

Capital One Communications Leader Debt Financing

Capital One Healthcare Managing Director Debt Financing

Capital One Healthcare Sr. Vice President Debt Financing

Capital One Healthcare Sr. Vice President Debt Financing

Catalyst Biosciences, Inc. CEO hemophilia, immunology and inflammatory disease

Celgene Alliance Management Executive Director oncology, inflammation and immunology

CellSight Technologies CEO oncology

CerRx CEO oncology

Chiesi Corporate Licensing Director Rare disease, hospital and specialty marketing

Cidara Therapeutics CBO anti-infectives and immunotherapy platform

Collegium Pharma Associate Director, Business Development

next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases

Conatus Pharmaceuticals Vp Business Development Liver Disease/NASH

Corium International CFO drug delivery

Corium International CBO drug delivery

Cortice Biosciences CEO Oncology

Cote Orphan Business Development Manager regulatory group with a laser focus on Orphan Drugs

CRG Managing Director Investment management firm

CRG President Investment management firm

More relevant attendees for better quality meeting output. BioNetwork West attracts C-level executives and VPs from large pharma, the most innovative biotech firms, academic institutions, foundations, and venture capital firms. Confirmed attendees include:




CRG Managing Director Investment management firm

CRISPR Therapeutics Vice President, Strategy Gene based medicine

CSL Behring VP Corporate Strategy & Business Development

Hematology-non-oncology(Hemophilia,Thrombosis, Hemostasis)Immunology-non-oncology, Cardiovascular/Metabolic Pulmonology,Transplant, Neurology, Seasonal Infectious Disease, Smart Devices Point of Care Diagnostics

CURx Pharmaceuticals CEO Rare Diseases, Cystic Fibrosis

CymaBay Therapeutics, Inc. Vp, Business Development Rare/Orphan Diseases (Anti-inflammatory/Gout, Diabetes, Lipid & Cardiovascular Disorders)

Daiichi Sankyo Director Licensing cardiovascular-metabolics, oncology, kidney disease, osteoporosis

Deerfield Management Partner Investment management firm

Depomed Corporate Development Vice President Pain and CNS

Depomed Business Development Vice President Pain and CNS

Depomed Senior Business Development Vice President Pain and CNS

Dermira Sr. Director Corporate Dev & Strategy Dermatology

Dicerna Chief Business Officer Oncology

DRI Capital Inc. Principal Royalty Financing

DRI Capital Inc. Managing Director Royalty Financing

DRI Capital Inc. Director, Business Development Royalty Financing

Eli Lilly Corporate Business Development Vice President

oncology, neuroscience, diabetes, ummunology, drug delivery, cardiovascular

EMD Serono Head of Global Licensing and Business Development and Alliance Management

neurodegenerative diseases, oncology, fertility, endocrinology, diabetes, cardiovascular diseases , relieving muscle, joint and back pain, colds and headaches, allergen immunotherapy

EMD Serono / Merck KGaA Head, Global Licensing & Business Development, Immunology

neurodegenerative diseases, oncology, fertility, endocrinology, diabetes, cardiovascular diseases , relieving muscle, joint and back pain, colds and headaches, allergen immunotherapy

Emergent BioSolutions Senior Director, Corporate Strategy infectious diseases

Enable Injections Vice President, Corporate Development Drug Delivery

EvaluatePharma USA Manager, Sales and Solutions - West Coast market intelligence and analysis company

FivePrime Therapeutics Chief Business Officer and Senior Vice President of Business Development oncology and inflammatory disease

Flamel Inc. Vp, Corporate & Business Development Drug Delivery

Foley Hoag Partner Law Firm

Foley Hoag LLP Partner Law Firm

Genentech Director, Infectious Diseases oncology, immunology, neuroscience, metabolism, infectious disease, ophthamology

Gilead Sciences Senior Corporate Development and Alliance Management Director

HIV / AIDS, Liver Diseases, Hematology / Oncology, Cardiovascular, Inflammation / Respiratory

BioNetwork West 2016 AttendeesCompany Job Title Therapeutic Area

GlaxoSmithKline Business Development Director HIV and infectious diseases, oncology, immuno-inflammation, respiratory and rare diseases

GLG Business Development Manager consulting firm

GLG Senior Business Development Associate consulting firm

GlobalData PLC Business Development Director research and consulting

GlycoMimetics, Inc. Vp, Corporate Development sickle cell, oncology

Guidepoint Director, Business Development Consulting Firm

Guidepoint Head of Global Corporate Sales consulting firm

Guidepoint Vice President, Corporate Business Development consulting firm

Halozyme Manager, Business Development & Strategy oncology, drug delivery platform

Halozyme Innovation Vice President oncology, drug delivery platform

Healthcare Royalty Pharma Director of Business Development Royalty Financing

Helsinn Therapeutics Vice President, Business Development cancer care and metabolism

Heracles Pharmaceuticals Director of Business Development smoking cessation drugs

Horizon Pharma Senior Vice President of Business Development and Alliance Management primary care, rheumatology and orphan disease markets

Horizon Pharma Director of Business Development primary care, rheumatology and orphan disease markets

Humanetics Corporation CEO oncology

ideaPoint CEO software for partnering, collaboration, grant management

ideaPoint VP, Business Development software for partnering, collaboration, grant management

Immunomic Therapeutics Senior Director of Corporate Development Vaccines and oncology

InCarda Therapeutics Inc. Chief Business Officer Cardiovascular Diseases

Indivior PLC Chief Business Development Officer Opioid Addiction treatment drugs

Inoviva, Inc. SVP & CBO Respiratory

Intellia Therapeutics Business Development Vice Presidentgene editing company, focused on the development of proprietary, potentially curative therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system

Intralinks Senior Account Executive, Life Sciences Secure document sharing and data rooms

Intralinks Director of Enterprise Sales Secure document sharing and data rooms

Intralinks Chief Marketing Officer Secure document sharing and data rooms

IntraLinks Ltd. Director, Life Sciences Strategy and Product Marketing Secure document sharing and data rooms

Janssen R&D US Head of Innovation cardiovascular and metabolism, Immunology, Infectious diseases and vaccines, neuroscience, oncology

Johns Hopkins Technology Ventures

Business Development and Corporate Partnerships Director commercialization arm of Johns Hopkins IP





Johnson & Johnson Venture Investments Vice President cardiovascular and metabolism, Immunology, Infectious diseases and vaccines, neuroscience, oncology

Johnson & Johnson The Janssen Pharmaceutical Companies

Head of Janssen Innovation External Partnering Strategy

cardiovascular and metabolism, Immunology, Infectious diseases and vaccines, neuroscience, oncology

JSK Therapeutics Chief Medical Officer oncology

Juno Therapeutics Senior Director, Business Development novel cellular immunotherapies

Juventas Therapeutics Associate Director, Business Development and Analytics non-viral gene therapies that activate natural processes to repair the body

Kastle Therapeutics Director of Business Development Rare diseases

Kastle Therapeutics VP Business Development rare diseases

Keystone Nano CEO oncology

KLOX Technologies CEO dermatology, wound care, and oral health

Kowa Pharmaceuticals Vice President of Trade and Business Development cardio metabolic therapeutics

Ligand Pharmaceuticals Vice President oncology, CNS, inflammation, metabolic disease, hematology, cardiology, anti-viral, ophthalmology, anti-microbial

Lupin Pharmaceuticals, Inc. Senior Business Development Vice President infection, diabetes, anti-inflammatory and respiratory, pediatric space

MabVax Therapeutics Cbo anti-cancer therapeutic and cancer diagnostic products

Macrogenics CBO oncology, autoimmune and infectious diseases

Mallinckrodt Pharmaceuticals Business Development and Licensing Vice President

autoimmune and rare diseases, intrathecal products, pain management, opioids products, central nervous system

Marathon Pharmaceuticals LLC Vice President Business Development CNS - Neurology

Marathon Pharmaceuticals LLC CFO CNS-Neurology

Medivation Senior Director of Business Development oncology

Memgen CEO oncology immunotherapy

Memgen Chief Scientific Officer oncology immunotherapy

Merck & Co Business Development and Licensing Executive Director

women's health, diabetes and endocrinology, cardiovascular, infectious disease, neuroscience , oncology, respiratory & Immunology, vaccines

Merck & Co Worldwide Licensing Director women's health, diabetes and endocrinology, cardiovascular, infectious disease, neuroscience , oncology, respiratory & Immunology, vaccines

Merck KGaA, Darmstadt, Germany

Head, Global Licensing & Business Development, Immunology


Merck KGaA, Darmstadt, Germany

Director, Search & Evaluation, ImmunoOncology


Mirati Therapeutics Director, Business Development Oncology

Mitsubishi Tanabe Pharma Holdings America, Inc. Vice President autoimmune, severe chronic diseases, metabolic disease, vaccine

Morrison Foerster Partner Law firm

MPM Capital, Inc. Managing Director multi-disciplinary investment company


Nabriva Therapeutics Chief Development Officer & Head, Business Development Infectious Diseases - Anti-bacterial agents

National Cancer Institute SBIR Program Director The federal government's principal agency for cancer research

Neonc Technologies CEO Central Nervous System/Oncology

Neonc Technologies COO CNS/Oncology

New Leaf Venture Partners Partner venture capital firm

Novartis Head of Business Development & Licensing

oncology, primary care, eye care, biopharmaceuticals & oncology injectables, and anti-Infectives

Novartis Business Development and Licensing Executive Director

oncology, primary care, eye care, biopharmaceuticals & oncology injectables, and anti-Infectives

Noven Pharmaceuticals, Inc. Business Development Vice President Women's Health, CNS/ADHD, Transdermal drug delivery

Novo Nordisk Innovation Sourcing Director diabetes care, rare bleeding disorders, growth hormone-related disorders, and obesity

Ocera Therapeutics CBO Acute and chronic orphan liver diseases

Oncoceutics CBO Oncology

Oncolys Vice President, Business Development oncology

Ora Inc. Director of Business Development CRO

OrbiMed Advisors Venture Partner rivate equity and venture capital firm

Organovo Business Development Vice President bio printing of human tissue

Pacira Pharmaceuticals Director of Business Development pain

Paranta Biosciences Director Commercialization & Business Development

early stage drug development company with focus on inflammation and fibrosis

Paranta Biosciences Ceo early stage drug development company with focus on inflammation and fibrosis, respiratory diseases

Pfizer Director, External Collaborations & Scientific Alliances

Immunology & Inflammation, CV & Metabolic Diseases, Oncology, Vaccines, Neuroscience & Pain, Rare Disease

Pfizer Venture Capital Executive Director Immunology & Inflammation, CV & Metabolic Diseases, Oncology, Vaccines, Neuroscience & Pain, Rare Disease

Pfizer Worldwide Business Development Vice President

Immunology & Inflammation, CV & Metabolic Diseases, Oncology, Vaccines, Neuroscience & Pain, Rare Disease

Pimera Inc President & Ceo Oncology

Pimera Inc Chief Scientific Officer Oncology

Pimera Inc Consultant Oncology

PPD Biotech Executive Director, Biotech Client Solutions CRO

PPD Biotech Vice President, Global Medical Officer CRO

PPD Biotech Senior Vice President and Global Head CRO

Prometheus Laboratories Inc Senior Business Development Director Gastroenterology, oncology and urology





Prometheus Labs Executive Director, Global Commercial Development Gastroenterology, oncology and urology

Purdue Pharma Executive Licensing and Business Development Director pain and drug delivery

QB3 Director of Industry Alliances Biotech Incubator

Quintiles Director, Business Development, Europe - Integrated Market Access CRO

Quintiles Vice President – Emerging BioPharma Commercial Solutions CRO

Raptor Pharmaceuticals Director of Corporate Development Rare Diseases, Cystic Fibrosis & cystinosis

Recordati Rare Diseases Business Development and Portfolio Strategy Director orphan disease

Redhill Biopharma Senior VP Business Development and Licensing

inflammatory and gastrointestinal diseases, including gastrointestinal cancers, CNS

Regeneron Pharmaceuticals Senior VP Business Development oncology, cardiovascular & metabolism, infectious disease, inflammation, ophthalmology, pain

Regulus Therapeutics COO Development of microRNA-based drugs targeting fibrosis, metabolism and cardiovascular diseases, cancer, HCV and immune-related diseases

Resverlogix Corporation Senior Business and Corporate Development Vice President Cardiovascular disease

RxC International Executive Partner Pharmaceutical Consultants

Salk Research Institute Senior Director of Tech Transfer Research Institution

Sanofi Global Head of Business Development & Licensing

Cardiovascular Disease, Degenerative Diseases, Diabetes, Immune-Mediated Diseases, Infectious Diseases, Multiple Sclerosis, Oncology, Ophthalmology, Rare Diseases, Vaccines

Sentynl Therapeutics CEO Pain, Inflammation, CNS

Sentynl Therapeutics CFO Pain, Inflammation, CNS

Sequence Bio CBO

Sequence Bio is a data-driven biotechnology company based in St. John’s, Newfoundland and Labrador, that is leading a 100,000 person genome research project (the 100k Genome Research Project). This project will engage people from across Newfoundland and Labrador and is a unique and remarkable opportunity to transform drug discovery by using data compiled from our unique genetic makeup to find new cures and develop better, safer medicines - all while returning benefits back to patients and the healthcare system.

SFJ Pharmaceuticals Vice President, Business Development oncology and autoimmune disease

Signpath Pharma Vice President, Business Development Oncology, CNS, Cardiovascular

Sorrento Therapeutics CFO Cellular Therapy, Antibodies, Immuno Oncology, Bio Similars

Sorrento Therapeutics SVP Immunotherapy and Head of Research & Global Partnerships Cellular Therapy, Antibodies, Immuno Oncology, Bio Similars

Southern Research Drug Discovery Division Director Research Institution

Spark Therapeutics CBO Gene Therapy


Spectrum Pharmaceuticals Director, Corporate & Business Development oncology

Spectrum Pharmaceuticals Vice President, Corporate & Business Development oncology

STATKING Clinical Services Executive Vice President CRO

Supernus Pharmaceuticals VP Corporate Development neurology and psychology

Tapimmune President & COO Immuno oncology

Teikoku Pharma Senior Director of Business Development Drug delivery in CNS, Pain and Oncology

Teva Pharmaceuticals Director, S&E, Biologics CNS, respiratory, oncology, women's health, biosimilars,

Therabron Therapeutics Chief Business Officer platform of novel therapeutic proteins in an effort to change how a variety of neglected and undertreated respiratory conditions are managed

Tizona Therapeutics COO Immunology

Tocagen Vp Business Development And Marketing oncology and immunology

Tracon Pharmaceuticals Vice President Business Development Oncology

Tulane University Chief Business Officer Academic Institution

United Therapeutics Business Development Associate Vice President chronic and life-threatening conditions

University of California DavisAssociate Vice Chancellor Of Technology Management And Corporate Relations

Academic Institution

University of Chicago Senior Project Manager Academic Institution

University of Chicago Associate Project Manager Academic Institution

Vaxiion Therapeutics Chief Operating and Scientific Officer drug delivery system based on its targeted bacterial minicell (BMC) technology for use in cancer

Vectron Biosolutions Chief Executive Officer technology platform for production of recombinant proteins in E. coli

Veloxis Vp, Strategy & Corporate Development Transplant Medicine

Viscadia President Pharmaceutical Consultants

Viscadia Founder & CEO Pharmaceutical Consultants

West-Ward Pharmaceuticals Business Development, Assistant Director primary care and rheumatology

West-Ward Pharmaceuticals Executive Director, Commercial Business Development primary care and rheumatology

Xbiotech Vp, Business Development antibody therapies for multiple indications including oncology and infectious disease,



Sponsorship OpportunitiesThis is your opportunity to align yourself with active deal makers as an integral part of a new partnership. Add some flesh to your press releases and ensure the biopharma industry understands your partnering aspirations, services or solutions. With a wide range of branding, business development and lead generation opportunities available, BioNetwork West is your best opportunity to accomplish your marketing and business development goals.

BioNetwork West sponsors take advantage of:• Exclusive access to C-level and VP biopharma business

development executives actively making deals

• Lead generation to accelerate your sales cycle

• Build loyalty with your clients to consolidate your market position

• Differentiate your company from other vendors for competitive advantage

• Raise awareness and remind the market that you are an essential partner

For more details on how you can showcase your offerings, contact Rachel Muser at 646.200.7524 or [email protected]


Lead Sponsors:

About Our Lead Sponsors

Back Back Life Science AdvisorsBack Bay Life Science Advisors is a strategic consulting and advisory firm dedicated to uncovering the deepest business insights for our clients so that they can thrive in a competitive, dynamic environment. We combine rigorous analytics and industry expertise to arrive at solutions that are often unexpected but always realistic and actionable. Our clients rely on us to create clarity for their toughest strategic decisions—those that will drive growth and value creation.

Back Bay senior leadership is involved from conception through delivery to ensure that the recommendations are actionable and that the strategies make sense. Our team reflects a mixture of scientific, clinical and commercial expertise, and deep understanding of the financial/transactional markets. This gives our clients a unique perspective on the factors that drive success in development and commercialization.

In combination with an extensive network across the industry, these factors equip us to develop the deep insights that lead to sustainable client advantages such as:

• Integrated scientific, clinical, commercial and transactional perspectives on growth opportunities.

• In-depth understanding of high-value market, patient and physician segments.

• Content-driven due diligence of attractive and feasible growth and investment strategies.

• Analysis of critical value drivers, and recommendations for differentiated corporate expansion or exit opportunities.

CapitalOne HealthcareCapitalOne Healthcare is a leading provider of financial services to the industry.Customers across healthcare sectors—including pharmaceuticals, medical devices,hospitals and outpatient services, healthcare IT, medical properties and long term care, —rely on Capital One Healthcare to finance acquisitions, refinance existing debt, support working capital needs and fund growth initiatives. Within-depth expertise, our team of professionals creates solutions tailored to meet the needs of our customers.& nbsp; Capital One Healthcare is a part of Capital One Commercial Banking, which leverages a relationship-based banking mode that seamlessly delivers an array of products and services including loans and deposit accounts, treasury management services, merchant services,investment banking, international services and correspondent banking.

CRGFounded in 2003, CRG (previously known as Capital Royalty L.P.) is a healthcare-focused investment firm with over $2 billion of assets under management that provides capital to healthcare companies primarily through structured debt and senior secured loans. CRG works across the spectrum of life science products and technologies and targets investment sizes ranging between $20 million and $300 million. The firm partners with commercial-stage healthcare companies to provide flexible financing solutions so they can achieve their growth objectives. CRG is headquartered in Houston, Texas with offices in Boulder, Colorado and New York City. For additional information, please visit www.crglp.com

DRI CapitalDRI Capital is a pioneer and global leader in healthcare investing and was the original innovator of the healthcare royalty market. The firm, originally called Drug Royalty Corporation, was founded in 1992 to purchase royalty streams on pharmaceutical products and to make healthcare equity investments. In 1993, the firm was listed on the Toronto Stock Exchange and remained publicly traded until 2002 when it was purchased by its current owners and taken private. In 2006, DRI Capital successfully raised $800 million ($240 million in equity and $560 million in debt) for its first managed fund, Drug Royalty I. With Drug Royalty I, DRI completed its transition to a private equity fund manager business model. In 2010, DRI successfully raised $926 million of capital commitments ($701 million in equity for its second managed fund, Drug Royalty II, and $225 million in equity for Drug Royalty II Co-Investment Fund). On September 9, 2013, DRI announced the final closing of its third managed fund, Drug Royalty III, with US $1.45 billion of equity commitments from a global pool of institutional investors.

As of June 30, 2014, Drug Royalty I, Drug Royalty II and Drug Royalty III have collectively acquired over 50 separate royalty streams from inventors, universities, research institutes, hospitals, biotechnology and global pharmaceutical companies payable on 30 different leading pharmaceutical products. In building this portfolio, DRI led the way with numerous milestone transactions, including the first transaction outside the United States, the first transaction with an individual inventor, the first transaction on a diagnostic, the first transaction on a life science tool and the first transaction involving a bundle of royalty streams. Further, DRI’s managed funds have completed more repeat transactions with prior counterparties than any other royalty monetization firms, reinforcing DRI’s leading reputation in the industry.


Today DRI Capital is a fully-integrated team of more than 30 investment professionals and support staff with well over U.S. $3 billion under management, focused on identifying, assessing, acquiring and managing biopharmaceutical royalty assets across the globe. Collectively, the professional team has over 150 years of experience. The team has individuals with backgrounds in the pharmaceutical industry, as well as in scientific, financial, healthcare, intellectual property and legal disciplines. This breadth of knowledge and training allows DRI Capital to identify unique potential investments and conduct its due diligence on such investments quickly and effectively.

EvaluateEvaluate is the trusted provider of life science commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors. We deliver quality, timely, must-have data and insights, and give expert support through a more personalised, flexible approach to help our clients make better decisions. Our online subscription services cover the pharmaceutical, biotech, medtech sectors and clinical trials. Our Custom Services group delivers project based analytical and data services. Vantage, our independent, award-winning editorial team, offers data-driven, forward-looking news, commentary and analysis on a daily basis. For more information visit www.evaluate.com. On Twitter: @EvaluatePharma, @EvaluateMedTech, @EPVantage

GuidepointGuidepoint, a leading expert network firm, gives professionals more confidence in their investment and strategic decisions by connecting them to specialized industry experts who can answer their most pressing business questions. Since its founding in 2003 by a bioorganic chemist, Guidepoint has set up more than 500,000 interactions between business professionals and experts in healthcare and beyond, all around the world. You have questions. We have experts. Learn more at www.guidepoint.com.

ideaPointideaPoint is the leading strategic growth and innovation management software solution for the global enterprise. With ideaPoint, you can scout, evaluate, invest-in, track and manage partnering and collaboration opportunities – all with one secure, simple tool.

ideaPoint provides full lifecycle management of BD/Licensing and Acquisition opportunities from scouting, to evaluation, to negotiation, to alliance management; while offering robust tracking and reporting capabilities. Clients include some of the world’s most successful BioScience companies.

ideaPoint brings to the enterprise a comprehensive toolset and our best practices to help companies better collaborate and partner in a secure virtual environment.

Morrison & FoersterWith depth of practice and global reach, Morrison & Foerster’s Life Sciences Group provides complete legal services to clients around the world. From concept to commercialization and through exit, our corporate, intellectual property and trial attorneys serve life sciences and healthcare companies, research institutions and the venture capital funds and investment banks that finance them, helping our clients protect their valuable assets and bring their ideas to market.

ViscadiaViscadia supports our Business Development & Licensing clients by helping executives identify and thoroughly evaluate acquisition/licensingtargets in alignment with portfolio and corporate strategy. We execute a disciplined decision support process, the cornerstone of which is the comprehensive and dynamic Viscadia ACE™ forecast model, supported by detailed primary and secondary market research, data room assessment and market landscape analysis. The findings and projections resulting from our process are distilled into a professional presentation suitable for executive audiences.

About Our Sponsors


About Our Media PartnersSince 1993, BioCentury Publications, Inc. has been internationally recognized as the leading provider of value-added information, analysis and data for biotechnology and pharmaceutical companies, investors, academia and government on the strategic issues essential to the formation, development and sustainability of life science ventures.

Bioprocess Online is the leading source of technical information, industry knowledge, and content for the biotherapeutic community. If you are a bioprocess engineer, scientist, bioprocessing manager, biotechnology producer, consultant, QA/QC, project manager, director, purchaser, marketer, or if you are involved in biopharm supply chain or facilities management, you now have access to a comprehensive Web community delivering the latest updates on the business and scientific information you need to succeed in your industry. From upstream to downstream processing through bio analysis and bio manufacturing, our goal is to provide readers with the most up-to-date information about the issues, challenges, and news they care about most. Bioprocess Online is part of the Life Science Connect media group. We strive to serve our subscribers by being the leading source of technology, management insight, and news information in the bioprocess industry. Please take a moment to joinour community and discover the benefits of your free membership. If you have any comments or questions, please contact us at [email protected].

CanBiotech is an open innovation and patient engagement platform for the biotech and pharmaceutical industries. Visit CanBiotech to learn more about best practices for collaboration with industry stakeholders and patients. Participate in the discussion, attend upcoming events and training opportunities provided by CanBiotech and our partners in the areas of innovation program development, open bioinnovation, design thinking for health and patient engagement.

Current Partnering was established in 2007 and has become the leading publisher of deal term reports within the life sciences. Designed to translate research into commercial success, Current Partnering provides an opportunity for the dissemination of the latest trends in partnering activity across the life sciences. Current Partnering report titles cover all aspects of partnering best practice and deal terms, providing users with the information and insight required to optimize their partnering activities. Please visit the website at http://www.currentpartnering.com

Drug Discovery Online is your single sources for everything related to discovery and early stage drug development. Our content includes news and opinions on the latest discovery technologies, from organic synthesis and the manual isolation of new compounds to combinatorial chemistry and high throughput screening. Visit www.drugdiscoveryonline.com today!

Georgia Bio (www.gabio.org) is the private, non-profit association whose members include pharmaceutical, biotechnology and medical device companies, medical centers, universities and research institutes, government groups and other business organizations involved in the development of life sciences related products and services.

Laboratory Network is the premier Internet source of useful and timely information about the laboratory industry. The site is directed to chemists, researchers, laboratory managers and research directors, as well as users, purchasers and manufacturers of laboratory equipment, chemicals, and supplies. Laboratory Network provides daily news updates and reports on business and technology trends vital to the industry.

Life Science Leader strives to be an essential business tool for Life Science executives. The editorial is designed to provide readers with content pertaining to the life cycle of Life Science Products and services. Our goal is to provide information that helps high-level industry personnel improve profits and overcome hurdles within the industry.

Medical News Today is the largest independent medical and health news site on the web - with 10,000,000 monthly unique users it is ranked number one for medical news on all major search engines. Medical News Today is used by pharmaceutical, biotech and health organizations, advertising agencies, PR companies and vertical ad networks to deliver targeted campaigns to HCPs, patients and caregivers. To find out how Medical News Today can help you to reach the right audience contact [email protected] or visit www.medicalnewstoday.com.

You’ve got a busy job, and you don’t have time to scour the internet for all the latest information on industry news and pharma suppliers. Connect with the whole industry at one location – PharmaceuticalOnline.com. Pharmaceutical Online has been serving the needs of pharmaceutical manufacturing professionals since 1997. We specialize in presenting the latest pharmaceutical innovations to a focused audience of engineering, plant management, and manufacturing professionals. www.pharmaceuticalonline.com


Lead Sponsors:

PharmaLeaders is an online environment dedicated to connecting, informing and educating more than 200,000 life sciences professionals. With breaking news, an extensive member network, job and events postings and more, industry executives, manufacturers, marketers and educators can count on PharmaLeaders for the tools they need to succeed in today’s competitive market environment. For more information, write to [email protected] or visit us online at www.pharmaleaders.com.

Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique Partnering Search service and its global network of industry experts to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing, and its sister service Medical Device Licensing (www.medicaldevicelicensingcom) are actively utilized by over 200,000 industry professionals each month. Pharmalicensing is a division of IP Technology Exchange, Inc.

PM360 is the premier, must-read monthly magazine for marketing decision makers in the pharmaceutical, biotech, and medical device industries. PM360 is the only journal that delivers practical how-to marketing information necessary for product managers/pharma marketing professionals to succeed in the complex and regulated healthcare environment. For more information, please visit: www.pm360online.com

PharmaVOICE magazine, reaching more than 41,000 BPA-qualified life-sciences executives, is the forum that allows business leaders to engage in a candid dialogue on the challenges and trends impacting the industry. PharmaVOICE provides readers with insightful and thought-provoking commentary in a multiple-perspective format through forums, topics, and articles covering a range of issues from molecule through market. PharmaVOICE subscribers are also kept abreast of the latest trends and information through additional media resources, including WebLinx Interactive WebSeminars, Podcasts, Videocasts, White Papers, E-Surveys and e-Alerts. Additionally, PharmaVOICEMarketplace.com provides a comprehensive directory of products, services, and solutions for the life-sciences industry. To Raise Your VOICE, contact [email protected].

About Our Media Partners


Registration InformationSmall Biotechs

Three Day Pass (Oct. 5-7, 2016)

$2,699

Excludes 15 minute Spotlight Upgrade

All Meals and Refreshments During the Conference

All Interactive Sessions and Keynotes

Access to One-to-One Meeting Rooms

Register Now

Three Day Pass (Oct. 5-7, 2016) & Spotlight Upgrade

$5,198

15 minute Spotlight Upgrade Included!




Register Now

Pharma/Big Biotechs Academics and Universities All Others

Three Day Pass (Oct. 5-7, 2016) Three Day Pass (Oct. 5-7, 2016) Three Day Pass (Oct. 5-7, 2016)

$3,899




$2,199




$4,299




Register Now Register Now Register Now

Biotech Spotlight: Highlight your organization in front of the larger audience in a 15 minute presentation to shed light on your organization, share new technologies, innovations and products and provide insight to the market on the partnerships you’re looking for. For more information or to book contact Mimi Fox, 1-416-597- 4808, [email protected].

Upgrade Opportunity

Please note: · All discounts are taken off the full conference price. No two discounts or offers can be combined. · Payment is due in full at the time of registration. Your registration will not be confirmed until payment is

received and may be subject to cancellation · Register online at www.bionetworkus.com or contact Mimi Fox, 1-416-597-4808, [email protected]. · Connecticut residents must add 6% sales tax to their registration fee

Delegate Substitutions And Cancellations: · You may substitute delegates at any time by providing reasonable advance notice to WBR. · For any cancellations received in writing not less than thirty (30) days prior to the conference, you will

receive a 75% credit to be used at another WBR conference which must occur within one year from the date of issuance of such credit. An administration fee of 25% of the contract fee will be retained by WBR for all permitted cancellations.

· There are no refunds given under any circumstances.

$6,299

15 minute Spotlight Upgrade To the Full Audience Before the 1:1 Meeting Rooms Open Included!




Register Now

Three Day Pass (Oct. 5-7, 2016) & Premium Biotech Spotlight Upgrade







partnering made easy - iqpc corporatethe ritz-carlton laguna niguel, ca october 5-7, 2016 partnering...

Documents